Boston Scientific Corp. (NYSE:BSX) won 510(k) clearance from the Food & Drug Administration and CE Mark approval in the European Union for its Advanix biliary stent.
The stent is designed to treat biliary strictures, abnormal narrowings of the common bile duct which can cause biliary stones and malignancies.
Natick, Massachusetts-based Boston Scientific said the new plastic biliary stent technology has improved deliverability and procedural control using the NaviFlex RX system, which the FDA cleared (PDF) along with the new stents. The regulatory clearances mean the devices are available in both the U.S. and European markets.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Boston Scientific managed to put some black ink on the books during the third quarter, despite posting a top-line slide of 5.4 percent.
The company posted profits of $190 million, or 12 cents per diluted share, on sales of $1.92 billion during the three months ended Sept. 30. That compares with a net loss of $94 million, or 6 cents per diluted share, on sales of $2.03 billion for Q3 2009.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.